{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:51:46Z","timestamp":1790621506284,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondazione Buzzi Unicem Onlus"},{"name":"Regional Committee for the Proposition of the Strategic Policy about Asbestos"},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["21-60-62-DINC"],"award-info":[{"award-number":["21-60-62-DINC"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although clinical antitumor activity of Tumor Treating Fields (TTFields) has been reported in malignant pleural mesothelioma (MPM) patients, the mechanisms behind the different selectivity displayed by the various MPM histotypes to this physical therapy has not been elucidated yet. Taking advantage of the development of well characterized human MPM cell lines derived from pleural effusion and\/or lavages of patients\u2019 thoracic cavity, we investigated the biological effects of TTFields against these cells, representative of epithelioid, biphasic, and sarcomatoid histotypes. Growth inhibition and cell cycle perturbations caused by TTFields were investigated side by side with RNA-Seq analyses at different exposure times to identify pathways involved in cell response to treatment. We observed significant differences of response to TTFields among the cell lines. Cell cycle analysis revealed that the most sensitive cells (epithelioid CD473) were blocked in G<jats:sub>2<\/jats:sub>M phase followed by formation of polyploid cells. The least sensitive cells (sarcomatoid CD60) were only slightly affected by TTFields with a general delay in all cell cycle phases. Apoptosis was present in all samples, but while epithelioid cell death was already observed during the first 24\u2009h of treatment, sarcomatoid cells needed longer times before they engaged apoptotic pathways. RNA-Seq experiments demonstrated that TTFields induced a transcriptional response already detectable at early time points (8\u2009h). The number of differentially expressed genes was higher in CD473 than in CD60 cells, involving several pathways, such as those pertinent to cell cycle checkpoints, DNA repair, and histone modifications. Our data provide further support to the notion that the antitumor effects of TTFields are not simply related to a non-specific reaction to a physical stimulus, but are dependent on the biological background of the cells and the particular sensitivity to TTFields observed in epithelioid MPM cells is associated with a higher transcriptional activity than that observed in sarcomatoid models.<\/jats:p>","DOI":"10.1038\/s41419-022-05073-4","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T07:03:50Z","timestamp":1657868630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations"],"prefix":"10.1038","volume":"13","author":[{"given":"Laura","family":"Mannarino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mirimao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Panini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Paracchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"Amodeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Libener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni L.","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-7870","authenticated-orcid":false,"given":"Monica","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"5073_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tranon.2014.12.002","volume":"8","author":"J Faig","year":"2015","unstructured":"Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8:35\u20139.","journal-title":"Transl Oncol"},{"key":"5073_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479\u201395.","journal-title":"Eur Respir J"},{"key":"5073_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"5073_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"5073_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329.","journal-title":"CA Cancer J Clin"},{"key":"5073_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"5073_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0140-6736(21)00147-1","volume":"397","author":"GL Ceresoli","year":"2021","unstructured":"Ceresoli GL, Pasello G. Immune checkpoint inhibitors in mesothelioma: a turning point. Lancet. 2021;397:348\u20139.","journal-title":"Lancet"},{"key":"5073_CR8","doi-asserted-by":"publisher","first-page":"e001601.","DOI":"10.1136\/jitc-2020-001601","volume":"9","author":"A Alay","year":"2021","unstructured":"Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Mar\u00edn R, et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer. 2021;9:e001601.","journal-title":"J Immunother Cancer"},{"key":"5073_CR9","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","volume":"20","author":"GL Ceresoli","year":"2019","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20:1702\u20139.","journal-title":"Lancet Oncol"},{"key":"5073_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046.","journal-title":"Sci Rep"},{"key":"5073_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","volume":"124","author":"O Rominiyi","year":"2021","unstructured":"Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour treating fields therapy for glioblastoma: current advances and future directions. Br J Cancer. 2021;124:697\u2013709.","journal-title":"Br J Cancer"},{"key":"5073_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","volume":"160","author":"H Mumblat","year":"2021","unstructured":"Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, et al. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. Lung Cancer. 2021;160:99\u2013110.","journal-title":"Lung Cancer"},{"key":"5073_CR13","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. 2020;90:102091.","journal-title":"Cancer Treat Rev"},{"key":"5073_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.21037\/atm-20-2920","volume":"8","author":"M Jiang","year":"2020","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage repair in cancer: from mechanisms to applications. Ann Transl Med. 2020;8:1685.","journal-title":"Ann Transl Med"},{"key":"5073_CR15","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.drudis.2020.09.035","volume":"25","author":"F Emadi","year":"2020","unstructured":"Emadi F, Teo T, Rahaman MH, Wang S. CDK12: a potential therapeutic target in cancer. Drug Disco Today. 2020;25:2257\u201367.","journal-title":"Drug Disco Today"},{"key":"5073_CR16","doi-asserted-by":"publisher","first-page":"102534","DOI":"10.1016\/j.isci.2021.102534","volume":"24","author":"S Xu","year":"2021","unstructured":"Xu S, Wu X, Wang P, Cao S, Peng B, Xu X. ASPM promotes homologous recombination-mediated DNA repair by safeguarding BRCA1 stability. iScience. 2021;24:102534.","journal-title":"iScience"},{"key":"5073_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/cdd.2015.165","volume":"23","author":"T Chernova","year":"2016","unstructured":"Chernova T, Sun XM, Powley IR, Galavotti S, Grosso S, Murphy FA, et al. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell Death Differ. 2016;23:1152\u201364.","journal-title":"Cell Death Differ"},{"key":"5073_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.30412","volume":"140","author":"R V\u00e1zquez","year":"2017","unstructured":"V\u00e1zquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, et al. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer. 2017;140:197\u2013207.","journal-title":"Int J Cancer"},{"key":"5073_CR19","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Disco. 2018;8:1548\u201365.","journal-title":"Cancer Disco"},{"key":"5073_CR20","doi-asserted-by":"publisher","first-page":"iii282","DOI":"10.1093\/neuonc\/noy139.251","volume":"20","author":"G Lavy Shahaf","year":"2018","unstructured":"Lavy Shahaf G, Giladi M, Schneiderman R, Kinzel A, Weinberg U, Kirson E, et al. P04.17 Cancer cell lines response to tumor treating fields: results of a meta-analysis. Neuro-Oncol. 2018;20:iii282.","journal-title":"Neuro-Oncol"},{"key":"5073_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59445-x","volume":"10","author":"YN Yoon","year":"2020","unstructured":"Yoon YN, Lee D, Park HJ, Kim J. Barium titanate nanoparticles sensitise treatment-resistant breast cancer cells to the antitumor action of tumour-treating fields. Sci Rep. 2020;10:2560.","journal-title":"Sci Rep"},{"key":"5073_CR22","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.3390\/cancers12103016","volume":"12","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Schneiderman RS, Volodin A, Shamir RR, Kaynan N, Zeevi E, et al. Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics. Cancers (Basel). 2020;12:3016.","journal-title":"Cancers (Basel)"},{"key":"5073_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.136","volume":"8","author":"NK Karanam","year":"2017","unstructured":"Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death Dis. 2017;8:e2711.","journal-title":"Cell Death Dis"},{"key":"5073_CR24","doi-asserted-by":"publisher","first-page":"896246","DOI":"10.3389\/fonc.2022.896246","volume":"12","author":"R Miller","year":"2022","unstructured":"Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, et al. Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma. Front Oncol. 2022;12:896246.","journal-title":"Front Oncol"},{"key":"5073_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4155\/fmc-2021-0036","volume":"13","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Jolly S, Benvegnu S, Jones EY, Fish PV. Small-molecule inhibitors of carboxylesterase Notum. Future Med Chem. 2021;13:1001\u201315.","journal-title":"Future Med Chem"},{"key":"5073_CR26","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2741\/1953","volume":"11","author":"S Fox","year":"2006","unstructured":"Fox S, Dharmarajan A. WNT signaling in malignant mesothelioma. Front Biosci. 2006;11:2106\u201312.","journal-title":"Front Biosci"},{"key":"5073_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.tcb.2018.08.005","volume":"29","author":"L Galluzzi","year":"2019","unstructured":"Galluzzi L, Spranger S, Fuchs E, L\u00f3pez-Soto A. WNT signaling in cancer immunosurveillance. Trends Cell Biol. 2019;29:44\u201365.","journal-title":"Trends Cell Biol"},{"key":"5073_CR28","doi-asserted-by":"publisher","first-page":"705384","DOI":"10.3389\/fonc.2021.705384","volume":"11","author":"WA Abreu de Oliveira","year":"2021","unstructured":"Abreu de Oliveira WA, Moens S, El Laithy Y, van der Veer BK, Athanasouli P, Cortesi EE, et al. Wnt\/\u03b2-catenin inhibition disrupts carboplatin resistance in isogenic models of triple-negative breast cancer. Front Oncol. 2021;11:705384.","journal-title":"Front Oncol"},{"key":"5073_CR29","first-page":"55820","volume":"123","author":"Y Porat","year":"2017","unstructured":"Porat Y, Giladi M, Schneiderman RS, Blat R, Shteingauz A, Zeevi E, et al. Determining the optimal inhibitory frequency for cancerous cells using tumor treating fields (TTFields). J Vis Exp. 2017;123:55820.","journal-title":"J Vis Exp"},{"key":"5073_CR30","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.3390\/ijms23105786","volume":"23","author":"L Mannarino","year":"2022","unstructured":"Mannarino L, Paracchini L, Pezzuto F, Olteanu GE, Moracci L, Vedovelli L, et al. Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study. Int J Mol Sci. 2022;23:5786.","journal-title":"Int J Mol Sci"},{"key":"5073_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907\u201315.","journal-title":"Nat Biotechnol"},{"key":"5073_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139.","journal-title":"Nat Methods"},{"key":"5073_CR33","doi-asserted-by":"publisher","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Parmigiani G, Johnson WE. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom Bioinform. 2020;2:lqaa078.","journal-title":"NAR Genom Bioinform"},{"key":"5073_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"5073_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter JD. Matplotlib: A 2D graphics environment. Comput Sci Eng. 2007;9:90\u20135.","journal-title":"Comput Sci Eng"},{"key":"5073_CR36","unstructured":"Waskom M, Olga B, Ostblom J, Lukauskas S, Hobson P, Gelbart M, et al. mwaskom\/seaborn: v0.10.0 (January 2020). 2020; Available at: https:\/\/zenodo.org\/record\/3629446#.YhNYG4qZNPa."},{"key":"5073_CR37","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5073_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L, Han Y, He Q. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"5073_CR39","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48:D498\u2013503.","journal-title":"Nucleic Acids Res"},{"key":"5073_CR40","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1371\/journal.pbio.0060184","volume":"6","author":"AR Pico","year":"2008","unstructured":"Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR, Evelo C. WikiPathways: pathway editing for the people. PLoS Biol. 2008;6:e184.","journal-title":"PLoS Biol"},{"key":"5073_CR41","doi-asserted-by":"publisher","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","volume":"5","author":"D Merico","year":"2010","unstructured":"Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5:e13984.","journal-title":"PLoS One"},{"key":"5073_CR42","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"5073_CR43","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754\u201360.","journal-title":"Bioinformatics"},{"key":"5073_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139.","journal-title":"Nat Biotechnol"},{"key":"5073_CR45","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44:e108.","journal-title":"Nucleic Acids Res"},{"key":"5073_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"5073_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0531-8","volume":"10","author":"D Tamborero","year":"2018","unstructured":"Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10:25.","journal-title":"Genome Med"},{"key":"5073_CR48","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12:e1004873.","journal-title":"PLoS Comput Biol"},{"key":"5073_CR49","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1093\/bioinformatics\/btaa554","volume":"36","author":"J Crowdis","year":"2020","unstructured":"Crowdis J, He MX, Reardon B, Van Allen EM. CoMut: visualizing integrated molecular information with comutation plots. Bioinformatics. 2020;36:4348\u20139.","journal-title":"Bioinformatics"},{"key":"5073_CR50","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","volume":"32","author":"ZL Skidmore","year":"2016","unstructured":"Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, et al. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32:3012\u20134.","journal-title":"Bioinformatics"},{"key":"5073_CR51","doi-asserted-by":"publisher","first-page":"118614","DOI":"10.1016\/j.bbamcr.2019.118614","volume":"1867","author":"R Amodeo","year":"2020","unstructured":"Amodeo R, Nifos\u00ec R, Giacomelli C, Ravelli C, La Rosa L, Callegari A, et al. Molecular insight on the altered membrane trafficking of TrkA kinase dead mutants. Biochim Biophys Acta Mol Cell Res. 2020;1867:118614.","journal-title":"Biochim Biophys Acta Mol Cell Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05073-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:07:02Z","timestamp":1669302422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05073-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["5073"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05073-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MATCH study complied with the Declaration of Helsinki and was conducted per Good Clinical Practice guidelines; it was approved by the Coordinating Ethics Committee \u201cASO SS. Antonio and Biagio and C. Arrigo\u201d on February, 20th 2019 (committee\u2019s reference number ASO.Meso.19.03) and then by the Ethics Committees of all other six study sites. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"612"}}